Are Current Medical Device Regulations Obsolete in an AI-driven, Digital Health Future?
HealthSpark, Episode 26: Ariel Stern, Alexander von Humboldt Professor for Digital Health, Economics, and Policy at the Hasso Plattner Institute and Professor at the University of Potsdam, examines how rapidly evolving algorithms and digital therapeutics are challenging legacy oversight systems, and what smarter, more adaptive policy approaches may require.
How should health systems respond to rapidly evolving medical devices?
Breakthrough innovations, like AI-driven diagnostics and digital therapeutics, are becoming critical for patient care, but they are advancing much faster than the regulatory frameworks designed to oversee them. Many of these new tools are software-based and continuously updated, and a single software change may impact clinical performance. This raises important questions about how these technologies are classified, evaluated, and monitored to make sure they remain safe and effective.
Can regulatory frameworks evolve through real‑world experimentation?
Some health systems are beginning to treat regulation itself as something to be tested and refined. They are testing regulatory sandboxes, pilot pathways, and time‑limited authorizations for certain types of digital products. These approaches allow new technologies to be introduced in controlled settings under close observation to collect data on performance, safety, and unintended consequences. The resulting evidence can then be used to revise approval pathways, post‑market requirements, and guidance so that regulation adapts based on real‑world use.
How can incentives be redesigned to reward better evidence and outcomes?
For many digital and device-based interventions, success depends on whether payment systems recognize and reward their value. Some countries are testing payment models that tie regulatory decisions to reimbursement and require manufacturers to demonstrate ongoing safety, effectiveness, and real-world impact. In practice, this could mean time‑limited coverage linked to data collection, higher payment for tools that improve outcomes, and withdrawal of payment for those that do not.
Key question to take forward:
As you watch the video and consider your own setting, you might reflect on:
What is the greatest opportunity to better align regulation, incentives, and evidence on new technologies to improve patient care?
